Leiden, The Netherlands, October 01, 2018 – DCprime announces today that Jeroen Rovers MD, PhD joins the company as its Chief Medical Officer with immediate effect. Jeroen trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel. In the past 15 years he worked in different academic institutes and companies, lastly at Kiadis Pharma where he in his role of Chief Medical Officer was part of the management team that took the company public on Euronext Amsterdam in 2015. Most of the products he worked on are related to specialized therapeutic areas, such as oncology, haematology and transplantation.
Jeroen Rovers comments: “It is an exciting time to join DCprime, as it’s products are moving further into clinical development. Cell based vaccins will potentially be an additional asset in the immunotherapeutic arsenal to prevent or reduce recurrence of cancer and to improve the of life of people living with cancer.”
Erik Manting, CEO of DCprime adds: “The appointment of Jeroen Rovers as Chief Medical Officer marks an important step in the development of DCprime as a company. We are transitioning from a technology-driven company to an organisation focused on achieving clinical results. We have launched an international PhII trial in AML with our lead product DCP-001 and aim to launch additional clinical trials in other cancer types in 2019. With Jeroen on board as an experienced CMO we will further strengthen our infrastructure and capabilities to bring cancer immunotherapeutics to clinic.”
About DCprime
DCprime is a privately owned, clinical stage biotechnology company focused on cancer immunotherapies. Founded in 2005, DCprime currently develops cell based cancer vaccines based on its proprietary technology platform DCOne®, with lead DCOne® asset DCP-001 being studied in patients with acute myeloid leukemia (AML). A completed Phase I study has demonstrated that DCP-001 is generally safe and capable of inducing a broad immune response. DCprime has received orphan drug designation from the European Medicines Agency for DCP-001 in AML and has commenced a multi-centre Phase II trial. DCprime intends to develop DCOne® based vaccines in other cancer indications, including multiple myeloma and solid tumours. For more information, visit www.dcprime.com.
Contact
Dr Erik Manting
CEO DCprime bv
e.manting@dcprime.com
+31629006169 (mobile)